- Supported exchanges /
- F /
- 04X.F
PERSONALIS INC. DL-001 (04X F) stock market data APIs
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
PERSONALIS INC. DL-001 Financial Data Overview
| 5.04 | |
| 5.04 | |
| - | |
| 5.04 | |
| 5.04 | |
| 0.8335-5.65 | |
| 0 | |
| 0 | |
| 80 027 K | |
| -0.34 | |
| 1.923 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PERSONALIS INC. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 80 027 K
- EBITDA -69 627 000
- Earnings Per Share -1.733
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get PERSONALIS INC. DL-001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.39
Get PERSONALIS INC. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
